Vipul Jairath, UEG Week 2022: Vedolizumab for mucosal healing in inflammatory bowel disease, the EARNEST trial

Vedolizumab has shown promise for achieving mucosal healing in patients with inflammatory bowel disease, the EARNEST trial shows. In this touchIMMUNOLOGY interview, we speak with Dr Vipul Jairath (Western University, University Hospital, London, ON, Canada) to discuss the importance of mucosal healing in inflammatory bowel disease as well as the findings and clinical implications of the EARNEST trial.

The abstract entitled ‘MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS’ (Abstract no: MP241) was presented at UEG Week, October 8 – 11, 2022.

Question:

1. What is known about the efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease? (0:22)
2. Why is mucosal healing such an important clinical endpoint in IBD? (1:09)
3. What were the aims and methodology of this analysis, and what were the findings of the analysis? (1:53)
4. What are the clinical implications of these findings? (3:22)

Disclosures: Vipul Jairath is a consultant for AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), Amgen, Applied Strategic, Arena Pharmaceuticals, Asahi Kasei Pharma, Asieris, AstraZeneca, BioJamp. Celgene/BMS,  Celltrion, Eli Lilly, Ferring, F. Hoffman-La Roche Ltd, Flagship Pioneering, Fresenius Kabi, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Organon (Merck), Landos BioPharma, Mylan, Pandion, Pendopharm, Pfizer,  Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva, Topivert, Ventyx Biosciences, Vividion Therapeutics. He is also a speaker’s bureau participant with Abbvie, Ferring, Galapagos, Janssen, Pfizer, Takeda.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of UEG Week 2022 

Access more content on Gastroenterology here